A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma.

Trial Profile

A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Rose bengal sodium (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Provectus Biopharmaceuticals
  • Most Recent Events

    • 01 Oct 2014 According to company's website, results published in the Annals of Surgical Oncology (Title- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma).
    • 29 Sep 2014 Data from overall analysis and sub-group data were announced in Provectus biopharmaceuticals media release.
    • 28 Sep 2014 Primary endpoint 'Objective Response Rate of Lesions' has been met, according to the 39th European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top